4 Results for "

BRCA1-deficient

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "BRCA1-deficient" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-124691
CAS No.: 688342-78-1
Purity:  99.70%
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

D-I03 is a selective RAD52 inhibitor with a Kd of 25.8 μM. D-I03 specifically inhibits RAD52-dependent single-strand annealing (SSA) and D-loop formation with IC50s of 5 μM and 8 μM, respectively. D-I03 suppresses growth of BRCA1- and BRCA2-deficient cells and inhibits formation of damage-induced RAD52 foci, but does not effect on RAD51 foci induced by Cisplatin [1] .
loading...
    loading...
Cat. No.: HY-174143
CAS No.: 1111188-09-0
Target:  

Apoptosis

Research Areas:  

Cancer

EXO1-IN-1 is a human exonuclease 1 (EXO1) inhibitor (IC50 = 15.7 μM). EXO1-IN-1 inhibits DNA end resection, promotes the accumulation of DNA double-strand breaks, and triggers S-phase polyamylation. EXO1-IN-1 induces apoptosis (Apoptosis) in BRCA1-deficient breast cancer cells. EXO1-IN-1 suppresses the growth of BRCA1-deficient breast cancer xenografts. EXO1-IN-1 can be used in research related to BRCA1-deficient breast cancer [1].
loading...
    loading...
Cat. No.: HY-133124
CAS No.: 2337386-47-5
Purity:  99.43%
Target:  

PARP PI3K Apoptosis

Research Areas:  

Cancer

PARP/PI3K-IN-1 (compound 15) is a potent PARP/PI3K inhibitor with pIC50 values of 8.22, 8.44, 8.25, 6.54, 8.13, 6.08 for PARP-1, PARP-2, PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, respectively. PARP/PI3K-IN-1 is a highly effective anticancer compound targeted against a wide range of oncologic diseases [1].
loading...
    loading...
Cat. No.: HY-171171
CAS No.: 2649242-85-1
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

NERx 329 is a replication protein A (RPA) inhibitor with an IC50 of 4.9 μM. NERx 329 blocks the interaction between RPA and single-stranded DNA, and induces functional RPA depletion, loss of single-stranded DNA gap protection, chromosome fragmentation and cell death. NERx 329 inhibits the DNA damage response signaling pathway, exhibits broad single-agent anticancer activity, and enhances the activity of DNA-damaging agents. NERx 329 can be used in research related to brca1-deficient breast cancer, non-small cell lung cancer, and brca1-deficient ovarian cancer [1] .
loading...
    loading...